Table 1 Descriptive analysis for all parameters used in scores/formulas, globally and by results from qRT-PCR screening test
qRT-PCR test | |||||
|---|---|---|---|---|---|
All | Positive | Negative | % missing | ||
Demographics | |||||
Age (years) | Total | 1618 | 519 | 1099 | 0% |
P50 (P25–P75) | 73.00 (62–82) | 72.00 (62–81) | 73.00 (62–82) | ||
Gender | Total | 1618 | 519 | 1099 | 0% |
Male (n, %) | 883 (54.6) | 320 (61.7) | 563 (51.2) | ||
Female (n, %) | 735 (45.4) | 199 (38.3) | 536 (48.8) | ||
Period | Total | 1618 | 519 | 1099 | 0% |
Wave 1 (n, %) | 588 (36.3) | 146 (28.1) | 442 (40.2) | ||
Between (n, %) | 204 (12.6) | 15 (2.9) | 189 (17.2) | ||
Wave 2 (n, %) | 826 (51.1) | 358 (69.0) | 468 (42.6) | ||
Comorbidities | |||||
Cardiac disease | Total | 593 | 268 | 325 | 63.3% |
Yes (n, %) | 200 (33.7) | 72 (26.9) | 128 (39.4) | ||
Immunosuppression | Total | 593 | 268 | 325 | 63.3% |
Yes (n, %) | 38 (6.4) | 11 (4.1) | 27 (8.3) | ||
Renal failure | Total | 594 | 268 | 326 | 63.3% |
Yes (n, %) | 48 (8.1) | 17 (6.3) | 31 (9.5) | ||
Symptoms | |||||
Fever | Total | 608 | 272 | 336 | 62.4% |
Yes (n, %) | 282 (46.4) | 169 (62.1) | 113 (33.6) | ||
Dry cough | Total | 607 | 272 | 335 | 62.4% |
Yes (n, %) | 220 (36.2) | 125 (46.0) | 95 (28.4) | ||
Wet cough | Total | 607 | 272 | 335 | |
Yes (n, %) | 106 (17.5) | 45 (16.5) | 61 (18.2) | ||
Dyspnea | Total | 608 | 272 | 336 | 62.4% |
Yes (n, %) | 403 (66.3) | 192 (70.6) | 211 (62.8) | ||
Diarrhea | Total | 607 | 272 | 335 | 62.4% |
Yes (n, %) | 128 (21.1) | 69 (25.4) | 59 (17.6) | ||
Biological parameters | |||||
LDH U/L | Total | 1618 | 519 | 1099 | 0% |
P50 (P25–P75) | 275 (219–368) | 349 (267–457) | 252 (205–318) | ||
CRP mg/L | Total | 1618 | 519 | 1099 | 0% |
P50 (P25–P75) | 60.40 (15.1–140.9) | 86.40 (43.6–164.2) | 41.40 (9.50–129.9) | ||
Procalcitonin µg/L | Total | 1615 | 588 | 202 | 0.2% |
P50 (P25–P75) | 0.10 (0.04–0.34) | 0.13 (0.06–0.34) | 0.09 (0.04–0.35) | ||
Lymphocytes 103/mm3 | Total | 1618 | 519 | 1099 | 0% |
P50 (P25–P75) | 1.01 (0.66–1.57) | 0.85 (0.61–1.19) | 1.12 (0.71–1.74) | ||
Basophils 103/mm3 | Total | 1618 | 519 | 1099 | 0% |
P50 (P25–P75) | 0.03 (0.01–0.05) | 0.02 (0.01–0.03) | 0.03 (0.02–0.05) | ||
Eosinophils 103/mm3 | Total | 1618 | 519 | 1099 | 0% |
P50 (P25–P75) | 0.03 (0.01–0.12) | 0.01 (0.00–0.03) | 0.07 (0.01–0.16) | ||
Ferritin µg/L | Total | 1614 | 519 | 1099 | 0.2% |
P50 (P25–P75) | 332.5 (145.1–762.7) | 702.00 (322.4–1441.4) | 248.28 (108.8–530) | ||
Leukocytes 103/mm3 | Total | 1618 | 519 | 1099 | 0% |
P50 (P25–P75) | 9.40 (6.61–12.76) | 7.02 (5.00–10.26) | 10.40 (7.83–13.90) | ||
Neutrophils 103/mm3 | Total | 1618 | 519 | 1099 | 0% |
P50 (P25–P75) | 7.09 (4.68–10.28) | 5.46 (3.50–8.51) | 8.03 (5.50–11.48) | ||
Chest X-ray | |||||
Radiological anomaly | Total | 1475 | 492 | 983 | 8.8% |
No (n, %) | 294 (19.9) | 37 (7.5) | 257 (26.1) | ||
Yes (n, %) | 1181 (80.1) | 455 (92.5) | 726 (73.9) | ||
Finding (n, %) | Total | 1475 | 492 | 983 | 8.8% |
No atypical signs | 825 (55.9) | 106 (21.5) | 719 (73.1) | ||
Subpleural or lower lung dominant distribution | 104 (7.1) | 56 (11.4) | 48 (4.9) | ||
Multilobar or bilateral lesion | 458 (31.1) | 301 (61.2) | 157 (16.0) | ||
GGO with or without consolidation | 88 (6.0) | 29 (5.9) | 59 (6.0) | ||
Alternative diagnosis (n, %) | Total | 1618 | 519 | 1099 | 0% |
More likely other diagnosis | 309 (19.1) | 15 (2.9) | 294 (26.8) | ||
Hard to determine | 1055 (65.2) | 379 (73.0) | 676 (61.5) | ||
More likely COVID-19 | 254 (15.7) | 125 (24.1) | 129 (11.7) | ||
Other finding (n, %) | Total | 1475 | 492 | 983 | 8.8% |
No infiltrate | 861 (58.4) | 122 (24.8) | 739 (75.2) | ||
Unilateral infiltrate | 129 (8.7) | 48 (9.8) | 81 (8.2) | ||
Bilateral infiltrate | 485 (32.9) | 322 (65.4) | 163 (16.6) | ||